– Data to support the development of EPI-321 as a one-time gene therapy treatment for facioscapulohumeral muscular dystrophy (FSHD) –
SOUTH SAN FRANCISCO, Calif. — May 4, 2023 — Epicrispr Biotechnologies, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced the acceptance of an abstract for oral presentation at the upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 16-20, 2023, in Los Angeles, Calif.
Full details of the presentation are as follows:
Presentation Title: “EPI-321, a Potential Cure for FSHD”
Session: Gene Targeting and Gene Correction: Hemoglobin, Muscle, and Eye
Date & Time: Friday, May 19, 2023, 4:00 p.m. PT
Abstract Number: 306
Location: Los Angeles Convention Center, Room 515 AB, Los Angeles, California
About Epicrispr Biotechnologies
Epicrispr Biotechnologies is a leading epigenome engineering company, leveraging the power of CRISPR without cutting DNA. The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies. Through the company’s library of the most compact Cas DNA-binding proteins to work on human cells, the company is developing in vivo therapies with delivery via a single AAV vector. Epicrispr Biotechnologies has an initial focus on facioscapulohumeral muscular dystrophy (FSHD) and is conducting additional research to address alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), as well as other indications. The company is financially backed by Horizons Ventures and other leading investors. Visit www.epicrispr.com for more information or follow us on Twitter and LinkedIn.
Investor Contact
Shawn M. Cox
Manager, Investor Relations, and Corporate Communications
shawn.cox@epic-bio.com
Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783